GLG News by Pancreatic Cancer Oncologists in the U.S.

The comprehensive clinical program will supplement the significant body of clinical data existing for ERBITUX in colorectal and head and neck cancers by exploring the use of ERBITUX in additional tumor types including brain, breast, bladder, gastric, lung, pancreas and prostate

The coverage restrictions placed on the FDA-approved indication have no scientific basis and are incompatible with good clinical practice," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Global Research and Development at Amgen. "We are concerned that inappropriately limiting coverage...

My understading id medicare need to cover all FDA indicated drugs. Here CMS violating FDA indication for Aranesp and procrit

Decrease use by 20-25% use of ESA. This may lead discounting and higher rebate from both amgen and orto-biotech to sustain market share. Since most of amgen contract with aranesp and neulasta use. It may effect use of neulasta. Next 6 month CMS may restrict use of Neulasta and neupogen for neutropenia...

Vaccine therpy has been of great interest in fight against cancer Vaccine therapy is likely to impact on natural history of cancer?

The mTOR class of drugs are going to be a success for renal cell cancer The mTOR drugs are likely to have broad appeal

CMS has ecome very aggressive about denying coverage of so called negative impact therapy What is the real motive behind the CMS debate and various therapies? Cancer care has seen this time and time again.

zanolimumab (HuMax-CD4) will contribute significantly to CTCL therapy zanolimumab (HuMax-CD4) has much potential in the market share

Is Lapatinib a major accomplishment for GSK? Was the recent phase III that led to approval understood? Are there threats to Lapatinib in the near furure?

The ASCO abstract WSJ article claims that meaningful information is available to some but not everyone simultaneously.  ASCO defends it policy by wishing to serve it's members at the potential expense of any other group.  Despite this uneven distribution of information, traders still seem...